Figures

Figure 1

Lymphocyte trafficking to the intestine…

Figure 1

Lymphocyte trafficking to the intestine and key molecules involved.

Figure 2

Rates of remission (CDAI<150) after different doses of natalizumab infusion compared with placebo. *Significant difference compared with placebo. ⁶

Figure 2

Rates of remission (CDAI<150) after different doses of natalizumab infusion compared with placebo. *Significant difference compared with placebo. ⁶

Figure 3

Rates of response (decrease in…

Figure 3

Rates of response (decrease in CDAI of at least 70 points from baseline)…

Figure 4

IBDQ scores in the four…

Figure 4

IBDQ scores in the four groups of patients. ⁶

Similar articles

• Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.

  Ghosh N, Chaki R, Mandal SC.Ghosh N, et al.Int Rev Immunol. 2012 Oct;31(5):410-27. doi: 10.3109/08830185.2012.690794.Int Rev Immunol. 2012.Retraction in:Int Rev Immunol. 2024 Nov 11:1. doi: 10.1080/08830185.2024.2423553.PMID:23083349Retracted.
• Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.

  Ghosh S.Ghosh S.Expert Opin Biol Ther. 2003 Sep;3(6):995-1000. doi: 10.1517/14712598.3.6.995.Expert Opin Biol Ther. 2003.PMID:12943458Review.
• Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.

  Lamb CA, O'Byrne S, Keir ME, Butcher EC.Lamb CA, et al.J Crohns Colitis. 2018 Aug 22;12(suppl_2):S653-S668. doi: 10.1093/ecco-jcc/jjy060.J Crohns Colitis. 2018.PMID:29767705Review.
• Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?

  Davenport RJ, Munday JR.Davenport RJ, et al.Drug Discov Today. 2007 Jul;12(13-14):569-76. doi: 10.1016/j.drudis.2007.05.001. Epub 2007 Jun 26.Drug Discov Today. 2007.PMID:17631252Review.
• [Perspectives in inflammatory bowel diseases treatment].

  Jalocha L, Wojtuń S, Dyrla P, Błaszak A, Wojtkowiak M, Zyśko B, Stelmaszuk T, Gil J.Jalocha L, et al.Pol Merkur Lekarski. 2009 May;26(155):556-8.Pol Merkur Lekarski. 2009.PMID:19606725Review.Polish.

Cited by

• Natalizumab for induction of remission in Crohn's disease.

  Nelson SM, Nguyen TM, McDonald JW, MacDonald JK.Nelson SM, et al.Cochrane Database Syst Rev. 2018 Aug 1;8(8):CD006097. doi: 10.1002/14651858.CD006097.pub3.Cochrane Database Syst Rev. 2018.PMID:30068022Free PMC article.
• Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine.

  Waldman E, Lu SX, Hubbard VM, Kochman AA, Eng JM, Terwey TH, Muriglan SJ, Kim TD, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR.Waldman E, et al.Blood. 2006 Feb 15;107(4):1703-11. doi: 10.1182/blood-2005-08-3445. Epub 2005 Nov 15.Blood. 2006.PMID:16291587Free PMC article.
• Optimizing the safety of biologic therapy for IBD.

  de Silva S, Devlin S, Panaccione R.de Silva S, et al.Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):93-101. doi: 10.1038/nrgastro.2009.221.Nat Rev Gastroenterol Hepatol. 2010.PMID:20134491Review.

References

Publication types

• Review

MeSH terms

• Antibodies, Monoclonal / therapeutic use*
• Antibodies, Monoclonal, Humanized
• Gastrointestinal Agents / therapeutic use*
• Humans
• Inflammatory Bowel Diseases / drug therapy*
• Inflammatory Bowel Diseases / immunology
• Integrin alpha4 / immunology*
• Natalizumab

Substances

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Gastrointestinal Agents
• Natalizumab
• Integrin alpha4

Related information

• PubChem Compound
• PubChem Substance

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Central